IMMMY22030 / TAK-573-1501 / LipeResearch Question:
Basic Study Information
Purpose:Location: University of Rochester
The main aims of this 3-part study are as follows:
Part 1: To determine any side effects from modakafusp alfa single treatment and how
often they occur. The dose of modakafusp alfa will be increased a little at a time
until the highest dose that does not cause harmful side effects is found.
Part 2: To assess clinical activity of one or more dosing schedules of modakafusp
alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone
standard dose will be administered with one or more selected dose of modakafusp alfa
in selected group of participants.
Part 3: To find the optimal dose with the more favorable risk-benefit profile of modakafusp
Participants will receive modakafusp alfa at one of two doses which will be given
through a vein.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search